NICE Guidelines and Medical Cannabis: What Prescribers Need to Know

NICE’s Role in Shaping UK Cannabis Prescribing

• NICE (National Institute for Health and Care Excellence) published guideline NG144 in November 2019
• NG144 restricts NHS cannabis prescribing to three conditions: intractable epilepsy in children, adults with chemotherapy-induced nausea, and adults with MS-related spasticity
• The private market operates outside these restrictions, allowing specialist prescribing for a broader range of conditions
• NICE is expected to update guidance as evidence accumulates — prescribers should monitor NICE Evidence Reviews regularly

The publication of NG144 was a defining moment in UK medical cannabis policy. By limiting NHS cannabis prescribing to three narrow indications, NICE effectively constrained access through the public health system whilst the private specialist sector expanded. Understanding the distinction between NHS commissioning restrictions and the legal ability to prescribe privately is essential for all prescribers operating in this space.

Current NHS-Funded Indications Under NG144

• Epidyolex (pharmaceutical CBD): licensed for Lennox-Gastaut syndrome and Dravet syndrome in children
• Sativex (nabiximols): commissioned for spasticity in MS where other treatments have failed
• Nabilone: licensed antiemetic for CINV, available via NHS oncology teams
• All other cannabis-based prescribing currently falls outside NHS commissioning frameworks and must be funded privately

It is important that prescribers communicate clearly with patients about the funding implications of cannabis prescribing. Many patients assume that a medical cannabis prescription will be NHS-funded following the 2018 rescheduling. The reality that most cannabis prescribing remains private, with significant out-of-pocket cost, must be addressed at the initial consultation to avoid misunderstanding and ensure informed consent.

Evidence Standards: Why NICE Found the Evidence Base Insufficient

• NICE requires randomised controlled trial (RCT) evidence for positive commissioning decisions
• The majority of cannabis evidence in 2019 was observational, retrospective, or from open-label studies
• NICE acknowledged promising signals in pain, anxiety, and PTSD but concluded evidence was insufficient for NHS commissioning
• Ongoing UK registry studies (e.g., UKCANN) aim to build the real-world evidence base for future NICE review

The evidence gap that led NICE to restrict NHS prescribing is being actively addressed through several UK and international research initiatives. Prescribers who participate in patient registries and contribute to clinical data collection are directly contributing to the evidence base that will inform future NICE guidance. This professional responsibility is an important aspect of ethical cannabis prescribing in the current environment.

Navigating Between NICE, GMC, and CQC Requirements

• GMC: prescribers must adhere to Good Medical Practice standards regardless of NICE guidance restrictions
• CQC: cannabis clinic inspections assess whether prescribing is appropriate, documented, and monitored
• Professional indemnity insurance: prescribers must confirm their coverage extends to cannabis prescribing
• Prescribe only within your area of specialist competence — do not prescribe beyond your clinical expertise

The regulatory landscape for cannabis prescribing involves multiple overlapping bodies. A prescriber who follows NICE guidance, meets GMC standards, satisfies CQC requirements, and maintains appropriate documentation is operating within the current framework effectively. Prescribers who are uncertain about any aspect of their obligations should seek guidance from their specialist society, Medical Defence Organisation, or the BHCA (British Hemp & Cannabis Association clinical standards body).